Explore All 633 Divestiture Medical Products Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | December 17, 2015 |
| Target | Bracco Diagnostics - Gastroenterology Business Unit |
| Sector | Medical Products |
| Buyer(s) | US Endoscopy |
| Sellers(s) | Bracco Diagnostics |
| Deal Type | Divestiture |
FILTER BY
US Endoscopy is a endoscopy device design and manufacturing, serving the U.S. and international gastrointestinal endoscopy markets. By listening and delivering solutions in the field of endoscopy, US Endoscopy's unique lines of proprietary devices provide better, more enhanced product options for GI clinicians.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Medical Products | 1 of 2 |
| Type: Divestiture | 1 of 1 |
| State: New Jersey | 1 of 1 |
| Country: United States | 1 of 2 |
| Year: 2015 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-04-07 |
Genii
St. Paul, Minnesota, United States Genii, Inc. is a medical device manufacturer specializing in electrosurgery products and accessories used in GI endoscopy procedures. Genii’s current products include a state-of-the-art electrosurgery generator unit (ESU) and an array of complementary disposable accessories. Genii, Inc. was founded in 2007 and is based in St. Paul, Minnesota. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1994 |
| Sector | Medical Products |
Bracco Diagnostics, Inc. is a developer and marketer of imaging agents for use in X-ray/computed tomography, nuclear medicine, and magnetic resonance imaging.
| Deal Context for Seller | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Medical Products | 2 of 2 |
| Type: Divestiture | 2 of 2 |
| State: New Jersey | 1 of 1 |
| Country: United States | 2 of 2 |
| Year: 2015 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-08-02 |
Bracco - Healthcare Protective Products Division
United States Bracco - Healthcare Protective Products Division includes the RSDL® (decontamination lotion) product that is cleared for marketing by the U.S. Food and Drug Administration (FDA) for removal or neutralization of chemical warfare agents from the skin, diversifies and broadens Emergent’s biodefense franchise into the chemical countermeasure market |
Sell | $26M |
